June 21, 2021
The HUTER Innovation Committee followed his scheduled as planned and debate took place between the Industrial Advisory Board experts and the HUTER consortia reaching amazing outcomes.
Date: June 21st 2021
The Innovation Committee was held on 21st June and all representatives from the different institutions joined the meeting that took place on a virtual way.
HUTER Innovation Committee consists of qualified representatives from each of the institutions performing research within the project. It is responsible for effectively planning for the post-project use of the results through both the commercial and new research routes. The HUTER Innovation Manager, Dr. Sergio Figueiras from BAHÍA Software leads the planning of the industrial exploitation route supported by the Communication and Dissemination Manager, Eugenia Flores (INCLIVA), to ensure that the dissemination activities serve as powerful tool for stimulating future use of the HUTER results.
To this meeting the Industrial Advisory Board Members invited joined for a productive discussion and the presentation of the outcomes from the questionnaire. During the hour and a half that lasted the technological issues and alienation with healthcare applications where presented as well as the possibilities of transferring research to the market.
The IAB experts in technology and scientific advisors from industry are supporting the Project consultations on the requirements and expectations for the HUTER Platform. This is allowing to get feedback for the initial industry driven functionalities which will result on a minimum of 3 industry-driven functionalities that will serve to improve the adaptability and usability of the future HUTER Platform to other cases (beyond the severe preeclampsia).
About the Industry Advisory - IAB
The IAB is a non-executive body constituted by representatives of innovative Biotech, Genetics, Clinics and IT companies (both SMEs and Large Enterprises) interested in the HUTER platform and the resulting tools and datasets to further contribute to their population, usage and exploitation.
About the Human Uterus Cells Atlas - HUTER
The human uterus is a flagship reproductive organ with profound implications not only in reproduction but also in women ́s health. HUTER can advance the Human Cell Atlas initiative for the exploitation potential in Obstetrics and Gynecology and biomedicine research areas such as Regenerative Medicine or Reproductive Medicine.
The uterus is itself a model for regenerative medicine since (i) endometrial tissue regenerates monthly and its transformation is executed through dynamic changes in states and interactions of multiple cell types, and (ii) myometrial tissue has remarkable regenerative capacity and extensive remodelling throughout pregnancy. Hence, the primary motivation HUTER proposal stems from the need to better understand the human uterus in order to more effectively address uterine diseases that impact women ́s health such as myomas or endometriosis and/or might contribute to infertility, infant and maternal mortality and morbidity.
HUTER technological and biological platform will be a crucial resource for the scientific and clinical communities to define the cellular basis of health and disease, allowing the rapid development of new diagnosis and prognosis tools and therapeutic advancements in the field.
Link to the project website: https://huter-hca.eu/